Trials / Completed
CompletedNCT00758069
Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)
Phase II Study on Sitagliptin -Assessment of Glucose-lowering Effects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 20 Years – 69 Years
- Healthy volunteers
- Not accepted
Summary
A clinical study determines the safety and efficacy of sitagliptin (MK0431) in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sitagliptin phosphate | 100 mg once daily (QD), taken orally for 4 weeks |
| DRUG | Comparator: Placebo | Placebo tablet, QD, taken orally for 4 weeks |
| DRUG | Comparator: Sitagliptin | 50 mg twice daily (BID), taken orally for 4 weeks |
Timeline
- Start date
- 2005-07-03
- Primary completion
- 2006-02-13
- Completion
- 2006-02-13
- First posted
- 2008-09-23
- Last updated
- 2017-05-05
- Results posted
- 2009-09-25
Source: ClinicalTrials.gov record NCT00758069. Inclusion in this directory is not an endorsement.